Dexcom Report: Tech Preferred Over Medication for Future of Type 2 Care

 

• At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it the most accurate CGM sensor.2
• New Dexcom G7 automated insulin delivery and smart insulin pen integrations also announced at ATTD reinforce the company’s status as the most connected CGM brand in the world.

https://www.businesswire.com/news/home/20250319951823/en/Dexcom-Report-Unveiled-at-ATTD-2025-Reveals-HCPs-Favour-Tech-Over-Medication-for-Future-of-Type-2-Care